Quantcast

Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™

VICTORIA, Seychelles–(BUSINESS WIRE)–Aptorum Group Limited (Nasdaq:APM) is excited to announce the launch and
issuance of its asset backed Smart Pharma Token (“SMPT”) by its
wholly owned subsidiary group, Smart Pharma group and Smart
Pharmaceutical Limited Partnership (“SPLP”) targeted in May 2019.

SPLP is extremely pleased to have jointly developed the SMPT token with
Aenco, an affiliated blockchain development company focused on
applications in the healthcare and financial sector. The SMPT token, an
ERC-1404 security compliant token, is a unique token that tokenizes
valuable pharmaceutical drugs and their underlying intellectual property
and associated allocation of cash flows induced by continual product
development and commercialization. It is the intention of the Smart
Pharma group to continue to incorporate Aenco’s blockchain technology
into its pharmaceutical development and commercialization processes.

Relying on intellectual property derived from the Smart-ACT™ platform,
Smart Pharma’s in-house new and repurposed drug discovery program, we
believe it will revolutionize drug discovery, in particular, drug
repurposing and repositioning. Smart-ACT™ stands for Accelerated
Commercialization of Therapeutics and encompasses state-of-the-art
technology in systematic screening of existing approved drug molecules
against selected therapeutic targets. Specifically, the Smart-ACT™
platform comprises a network of modules and processes that simulate the
effectiveness of drug molecules against diseases for outcome prediction
and selection. The Smart-ACT™ platform, in combination with in vitro and
in vivo validation studies, will initially focus on the screening for
drugs targeting orphan diseases or unmet medical needs with a target to
discover up to 10 new and promising drug candidates per annum.

The SMPT token is created to help foster a community ecosystem of
passionate and like-minded people in revolutionising the drug discovery
industry who would like to be an integral part of the process. SMPT
token is backed by SPLP’s assets, including intellectual property rights
of drug candidates created through the Smart-ACT™ program and any
royalty monetization income. The SMPT tokens are backed by the following:

    • intellectual property rights obtained from drug candidates discovered;
    • applicable royalties based on net sales of the licensed products made
      by Smart Pharma group upon successful commercialization of the drugs;
    • a percentage of sublicensing revenue received by Smart Pharma group
      from third party in regard to the licensed intellectual property
      rights; and
    • a percentage of consideration for assignment of the intellectual
      property rights to third parties.

SMPT token holder will allow them to benefit from the inherent valuation
growth of SPLP’s intellectual property portfolio as well as being
entitled to a portion of cash flows both upon any winding-up of SPLP or
upon distributions by SPLP (distributions can be made periodically at
SPLP’s discretion).

A spokesperson for Smart Pharma commented: “Our Smart-ACT™ platform is a
novel tool that will completely transform the drug repurposing and
discovery industry which traditionally relied on scattered and
serendipitous discoveries, with initial focus on orphan and unmet
diseases and backed by its parent company, Aptorum Group Limited. We are
excited to invite like-minded community and participants to join and
benefit from our exciting initiatives, through the SMPT token.”

SPLP plans to collaborate with a number of third party exchanges to
establish a secondary market for the SMPT token in Q2 2019 and further
information will be made available on its website and social media
platforms. The SMPT token will not be available for offer or sale to
participants who are residents of the United States and certain other
countries. All SMPT token holders will need to undergo a “whitelisting”
procedure through the SMTPH.com website in order to qualify for holding
of the token, which will involve compliance with know your customer
(KYC) and applicable anti-money laundering (AML) procedures.

Further information on the Smart-ACT™ platform can be found on our
website: http://www.smtph.com.

Further information on the Smart Pharma Token, SMPT, can be found on our
website: http://www.smtph.com/token.

Further information on Aenco can be found on the website: http://www.aencoin.com.

About Aptorum Group Limited

Aptorum Group Limited (Nasdaq:APM) is a pharmaceutical company dedicated
to developing and commercializing a broad range of therapeutic and
diagnostic technologies to tackle unmet medical needs. Aptorum Group is
pursuing therapeutic and diagnostic projects in neurology, infectious
diseases, gastroenterology, oncology and other disease areas as well as
non-therapeutic areas such as surgical robotics and the operations of
its medical clinic in Hong Kong, Talem Medical, with the initial focus
on treatment of chronic diseases resulting from modern sedentary
lifestyles and aging population.

For more information about Aptorum Group, please visit www.aptorumgroup.com.

About Smart Pharma

Smart Pharma’s holding company, SMTPH Limited, and its group companies
are wholly-owned subsidiaries of Aptorum Group Limited, focuses on
deploying its Smart-ACT™ platform to revolutionize pharmaceutical
discovery and development.

For more information about Smart Pharma, please visit www.smtph.com.

Disclaimer and Forward-Looking Statements

This press release includes statements concerning Aptorum Group Limited
and its future expectations, plans and prospects that constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. For this purpose, any
statements contained herein that are not statements of historical fact
may be deemed to be forward-looking statements. In some cases, you can
identify forward-looking statements by terms such as “may,” “should,”
“expects,” “plans,” “anticipates,” “could,” “intends,” “target,”
“projects,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential,” or “continue,” or the negative of these terms or other
similar expressions. Aptorum Group has based these forward-looking
statements largely on its current expectations and projections about
future events and trends that it believes may affect its business,
financial condition and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions including,
without limitation, risks related to its announced management and
organizational changes, the continued service and availability of key
personnel, its ability to expand its product assortments by offering
additional products for additional consumer segments, the company’s
anticipated growth strategies, anticipated trends and challenges in its
business, and its expectations regarding, and the stability of, its
supply chain, and the risks more fully described in Aptorum Group’s Form
20-F and other filings that Aptorum Group may make with the SEC in the
future. Aptorum Group assumes no obligation to update any
forward-looking statements contained in this press release as a result
of new information, future events or otherwise.

This communication shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be any
sale of securities in any jurisdiction in which the offer, solicitation
or sale would be unlawful prior to the registration or qualification
under the securities laws of any such jurisdiction. No offering of
securities shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as amended.

Investors must rely on their own evaluation of Aptorum and its
securities, including the merits and risks involved. Nothing contained
herein is or shall be relied on as, a promise or representation as to
the future performance of Aptorum Group or Smart Pharma group.

Contacts

For Aptorum Group Limited
Investor Relations and Media
Tel:
+852 2117 6611
Email: [email protected]
Website:
http://www.aptorumgroup.com

For Smart Pharma
Information Request
Tel: +852 2117 6611
Email:
[email protected]
Website: http://www.smtph.com

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.